Last $6.70 USD
Change Today +0.28 / 4.36%
Volume 84.9K
ATNM On Other Exchanges
As of 8:04 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

actinium pharmaceuticals inc (ATNM) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/3/14 - $15.00
52 Week Low
11/13/13 - $4.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

actinium pharmaceuticals inc (ATNM) Related Businessweek News

No Related Businessweek News Found

actinium pharmaceuticals inc (ATNM) Details

Actinium Pharmaceuticals, Inc., a biotechnology company, develops drugs for the treatment of cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform. Its products include Bismab-A for acute myeloid leukemia; Actimab-A, an antibody-drug construct that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia; and Iomab-B, an antibody-drug construct used in myeloconditioning for hematopoietic stem cells transplantation in various indications. The company was formerly known as Cactus Ventures, Inc. and changed its name to Actinium Pharmaceuticals, Inc. in April 2013. Actinium Pharmaceuticals, Inc. was founded in 2000 and is based in New York, New York.

6 Employees
Last Reported Date: 03/19/14
Founded in 2000

actinium pharmaceuticals inc (ATNM) Top Compensated Officers

Chief Executive Officer, President, Interim C...
Total Annual Compensation: $112.1K
Chief Operating Officer and Chief Medical Off...
Total Annual Compensation: $295.5K
Compensation as of Fiscal Year 2013.

actinium pharmaceuticals inc (ATNM) Key Developments

Actinium Pharmaceuticals, Inc Appoints Richard E. Champlin to Scientific Advisory Board

Actinium Pharmaceuticals, Inc. announced the addition of Richard E. Champlin, M.D. of MD Anderson Cancer Center to its Scientific Advisory Board (SAB) for Iomab(TM)-B, the company's radioimmunotherapy asset which is preparing to enter a Phase III pivotal trial. Dr. Champlin is in his twenty-fifth year at MD Anderson Cancer Center in Houston, Texas. He holds the titles of Chair, Department of Stem Cell Transplantation and Cellular Therapy; Professor of Medicine; and Associate Division Head, Division of Cancer Medicine.

Actinium Pharmaceuticals, Inc. Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 through Oct-01-2014

Actinium Pharmaceuticals, Inc. Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 through Oct-01-2014. Venue: Congress Center Basel, MCH Messe Schweiz (Basel) AG, CH-4005 Basel, Switzerland. Presentation Date & Speakers: Sep-30-2014, Dragan Cicic, Chief Operating Officer and Chief Medical Officer, Sandesh C. Seth, Chairman and Member of Compensation Committee.

Actinium Pharmaceuticals, Inc. Files Orphan Drug Application for Use of Actimab-A in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients

Actinium Pharmaceuticals, Inc. announced that it has filed an application for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for Actimab-A, a radiolabeled antibody being developed for newly diagnosed AML in patients over 60, and is currently in a multicenter Phase 1/2 clinical trial. The company expects to provide interim results for the Actimab-A trial around the same time as the American Society of Hematology (ASH) meeting in December 2014. Patients over age 60 comprise the majority of those diagnosed with acute myeloid leukemia (AML), but treatment approaches in this population are limited because a majority of these individuals are judged too frail and unable to tolerate standard induction chemotherapy. Orphan drug designation is granted to treatments that are expected to provide significant therapeutic advantage over existing treatments and that target conditions affecting 200,000 or fewer U.S. patients per year. Orphan-designated drugs are eligible for incentives such as a faster approval process and additional market exclusivity. Actimab-A is a radiolabeled antibody being developed for newly diagnosed AML in patients over 60, and is currently in a multicenter Phase I/II clinical trial. Based on Actinium's alpha-particle immunotherapy (APIT) platform, Actimab-A consists of the CD33 antibody lintuzumab linked to the actinium-225 payload. Actimab-A has attracted support from experts at the high-volume cancer treatment hospitals due to the potential of its safety and efficacy profile, as well as its potential potency, specificity and ease of use. Clinical trials are being conducted at cancer institutions such as Memorial Sloan Kettering Cancer Center, Johns Hopkins Medicine, University of Pennsylvania Health System, Fred Hutchinson Cancer Research Center, MD Anderson Cancer Center and the Texas Oncology-Baylor Charles A. Sammons Cancer Center. The Company expects interim Phase I/II clinical trial results in December 2014. Actimab candidates are in early development for other cancers.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATNM:US $6.70 USD +0.28

ATNM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ATNM.
View Industry Companies

Industry Analysis


Industry Average

Valuation ATNM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 40.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTINIUM PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at